Myriad Genetics, Inc. (MYGN)
$4.08-2.86%Close
BUYRECOVERY · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $385M
- Short % float
- 9.94%
- Days to cover
- 4.3
- SI change
- -8.6%
Industry peers
FMP comparable companies · ranked by market cap
- NTRABUYNatera, Inc.$56.7BBULLQ 30$395.65-0.53%
- GHSELLGuardant Health, Inc.$21.8BBEARQ 23$162.09-0.43%
- QGENBUYQiagen N.V.$9.4BRECOVERYQ 16$45.44+0.29%
- BLLNSELLBillionToOne, Inc.$4.3BCRISISQ -9$94.44+1.47%
- VCYTBUYVeracyte, Inc.$3.4BBEARQ 14$43.11-2.07%
- PSNLSELLPersonalis, Inc.$1.7BBEARQ 6$15.85+0.32%
- FLGTSELLFulgent Genetics, Inc.$598MRECOVERYQ 13$21.06-1.91%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
NO COVERAGECompany news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on MYGN?
- LOPJLB’s latest quantitative signal on Myriad Genetics, Inc. (MYGN) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is MYGN in?
- Myriad Genetics, Inc. (MYGN) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Myriad Genetics, Inc. (MYGN) do?
- Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, womenâs health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, …